from EVD was 529/µL on August 9, 2016. He reported compliance with his ART regimen and denied any serious illness since the time of his HIV diagnosis.

The patient enrolled in the Men’s Health Screening Program on October 21, 2015. Per program protocol, his semen was tested every 4 weeks for Ebola virus by RT-PCR using described methods (2). Specimens are considered positive if viral structural protein 40 gene and nucleoprotein gene targets of Ebola virus have Ct values <40, and indeterminate if only 1 gene target has a Ct <40. Since his enrollment in the program, the semen of the patient has been positive for Ebola virus RNA up to 565 days after he was discharged from the ETU. Ct values plateaued to indeterminate for samples up to 758 days after discharge (Figure). Although detection of Ebola virus RNA by RT-PCR does not necessarily indicate the presence of infectious virus, a previous study reported Ebola virus infectivity by RT-PCR–positive human semen samples in immunodeficient mice (3).

The prolonged period during which Ebola virus RNA was detected in this patient adds to evidence (2–4) that there is heterogeneity in duration of Ebola virus persistence in semen among survivors of EVD. Although etiology of this heterogeneity is unclear, possible explanations for this patient include age-associated effects (2), attenuated clearance caused by dual HIV infection, immunosuppression from etiologies other than HIV, severity of acute illness, or unknown host genetic factors. Although the patient had an adequate CD4 cell count, chronic inflammation, immune system dysregulation, and accelerated immunosenescence in well-controlled HIV patients have been described and are clinically manifested as early cardiovascular disease, neurocognitive disorders, metabolic syndrome, and non–AIDS-associated cancers (5). Therefore, co-infection with HIV might play a role in persistence of Ebola virus in semen, despite an adequate clinical response to ART.

Because HIV infection is treatable and testing is readily available in West Africa, semen testing programs for Ebola virus should consider offering HIV testing to male survivors of EVD with persistently detectable Ebola virus in semen. Furthermore, HIV care was interrupted during the Ebola outbreak in West Africa because of closure of clinics and interruption of ART distribution (6). This case-patient had a favorable outcome for EVD despite being HIV positive, which emphasizes the need for continuing treatment for HIV infection in the setting of a large-scale Ebola outbreak. In addition, this case highlights the need for a better understanding of the role that co-infection with HIV might play in persistent detection of Ebola virus RNA in male survivors of EVD.

Dr. Purpura is an Epidemic Intelligence Service Officer in the National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. His research interests include filoviruses and other viruses that cause hemorrhagic fevers.

References

Address for correspondence: Lawrence J. Purpura, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop A30, Atlanta, GA 30329-4027, USA; email: yxp0@cdc.gov

Treatment Failure of Dihydroartemisinin/ Piperaquine for Plasmodium falciparum Malaria, Vietnam

Bui Quang Phuc, Charlotte Rasmussen, Tran Thanh Duong, Le Than Dong, Mai Anh Loi, Didier Ménard, Joel Tarning, Dorina Bustos, Pascal Ringwald, Gawrie Loku Galappaththy, Nguyen Quang Thieu

Author affiliations: National Institute of Malariology, Parasitology, and Entomology, Hanoi, Vietnam (B.Q. Phuc, T.T. Duong, M.A. Loi, N.Q. Thieu); World Health Organization, Geneva, Switzerland (C. Rasmussen, D. Bustos, P. Ringwald, G.L. Galappaththy); Institute of Malariology, Parasitology, and Entomology, Ho Chi Minh, Vietnam (L.T. Dong); Institut Pasteur, Phnom Penh, Cambodia (D. Ménard); Mahidol University, Bangkok, Thailand (J. Tarning)

DOI: http://dx.doi.org/10.3201/eid2304.161872
We conducted a study in Binh Phuoc, Vietnam, in 2015 on the therapeutic efficacy of dihydroartemisinin/piperaquine for *Plasmodium falciparum* malaria. A high number of treatment failures (14/40) was found, and piperaquine resistance in Vietnam was confirmed. A change in the malaria treatment policy for Vietnam is in process.

The high failure rate of artemisinin-based combination therapy in the treatment of uncomplicated *Plasmodium falciparum* malaria has been a growing concern in the Greater Mekong Subregion of Southeast Asia. High numbers of treatment failures were reported for dihydroartemisinin/piperaquine in Cambodia (1), but efficacy of this drug has remained high in Vietnam since its introduction in 2003. We investigated dihydroartemisinin/piperaquine efficacy in the treatment of uncomplicated *P. falciparum* malaria in Binh Phuoc Province, Vietnam, during August–December 2015. We looked for molecular markers of drug resistance and determined piperaquine blood levels in treated patients to assess if piperaquine resistance was present in Vietnam. This study was approved by the ethics boards of the Ministry of Health in Vietnam and the Western Pacific Regional Office of the World Health Organization.

The National Institute of Malariaology, Parasitology, and Entomology conducted this study as part of routine surveillance on drug efficacy following the 2009 World Health Organization protocol (2). After obtaining written consent, patients (age of inclusion, 2–60 years) were enrolled and given dihydroartemisinin/piperaquine (Pharbacor, Hanoi, Vietnam) at a target dosage of 2.4 mg/kg for dihydroartemisinin and 18 mg/kg for piperaquine once a day for 3 days. Patients with treatment failures were subsequently given quinine hydrochlorate (30 mg/kg/d) and doxycycline (3 mg/kg/d) for 7 days. Primary endpoint was adequate clinical and parasitologic response (ACPR) on day 42; PCR genotyping, comparing day 0 and day of failure samples, was used to distinguish recrudescence from reinfection with another strain (2). Dried blood spots were collected on day 0 and analyzed for mutations in the *K13* propeller domain (3), *Pfmdr1* copy number (4), and *Pfplasmepsin2* (*PfPM2*) copy number (5), which are markers associated with artemisinin, mefloquine, and piperaquine resistance, respectively. By using a previously established relationship between capillary whole blood and venous plasma, piperaquine plasma concentrations were calculated from blood spots collected day 7 (6). Sequencing was done by the Institut Pasteur in Cambodia, and the piperaquine blood levels were assessed by the Mahidol Oxford Tropical Medicine Research Unit in Thailand.

Forty-six patients with uncomplicated *P. falciparum* malaria were enrolled; 44 were followed until day 42, and 2 were lost to follow-up after day 14. Mean age of enrolled patients was 26.9 (range 14–53) years, and 93% (43/46) were male. Geometric mean parasitemia on day 0 was 17,759 (range 1,514–97,454)/μL.

On day 3, half (23/46) of patients were parasitemic. On day 42, a total of 65% (26/40, 95% CI 48.3%–79.4%) had an ACPR, and 35% (14/40) had recrudescence; 4 were withdrawn because they became reinfected.

Artemisinin resistance is defined as delayed parasite clearance and is associated with mutations in the *K13* propeller domain, the most prevalent being the C580Y mutation in the eastern Greater Mekong Subregion (7). *K13* analysis of 42 samples (4 were excluded because of uninterpretable results) from our study showed that 90.5% (38/42) were C580Y and 9.5% (4/42) were wild-type. This C580Y prevalence is higher than that reported in a previous study done in Binh Phuoc in 2014, in which 34.5% of samples had the C580Y mutation (B.Q. Phuc, unpub. data).

Analysis of *PfPM2* showed that 25/46 (54.3%) samples had multiple copies of the gene. Of the 42 samples with known *K13* types, 22 (52.4%) had both C580Y and *PfPM2* amplifications. The remaining 3 had unknown *K13* types. All 46 samples had a single copy of *Pfmdr1*, indicating that all parasites were sensitive to mefloquine (4).

The average day 7 piperaquine plasma concentration (n = 42) was 35.7 (range 11.1–71.0) ng/mL. In 57.1% (24/42) of patients, this concentration was at or above the cutoff value (30 ng/mL) associated with adequate piperaquine exposure (1). For patients with ACPRs, the average concentration was 36.9 (range 17.2–71.0) ng/mL, and 57.7% (15/26) were adequately exposed. For patients that had recrudescence, the average concentration was 39.5 (range 12.4–65.7) ng/mL, and 72.7% (8/11) were adequately exposed.

Of the 14 patients who experienced recrudescence, 10 had parasites with the C580Y mutation and *PfPM2* amplifications, 3 had parasites with the C580Y mutation only, and 1 had parasites with an unknown *K13* type and *PfPM2* amplifications. *K13* mutations (found during routine surveillance conducted over the last 5 years in Vietnam) alone did not lead to dihydroartemisinin/piperaquine failures. The association between the presence of molecular markers and recrudescence is confounded by various factors, including parasite load, immunity, and drug levels. Of the 3 patients who had recrudescence and were infected with *P. falciparum* without *PfPM2* amplifications, 2 had inadequate piperaquine levels. Of the 11 patients who had recrudescence and an infection with *P. falciparum* with *PfPM2* amplifications, 7 had adequate piperaquine levels. Low piperaquine blood levels, irrespective of the presence of *PfPM2* amplifications, might play a role in some treatment failures. Treatment failures in cases with *PfPM2* amplification—positive parasites and adequate piperaquine exposure support the presence of piperaquine resistance in Vietnam.

Our results show that 1 *K13* mutation has become dominant and that piperaquine resistance is present in Vietnam. A change in the malaria treatment policy to treat with artesunate/mefloquine in Binh Phuoc Province is underway.
Acknowledgments
The authors would like to express their appreciation to all of the study patients.

This study was supported by the Bill and Melinda Gates Foundation and the US Agency for International Development via the World Health Organization.

The authors declare that there is no conflict of interest regarding the publication of this paper. D.B., C.R., G.G., and P.R. are staff members of the World Health Organization. D.B., C.R., G.G., and P.R. are solely responsible for views expressed in this publication, and they do not necessarily represent decisions, policies, or views of the World Health Organization.

Dr. Phuc is an associate professor and the Chief of the Department of Clinical Research, National Institute of Malaria, Parasitology, and Entomology, Hanoi, Vietnam. His primary research interests are clinical trials and drug efficacy in malaria.

References

Address for correspondence: Charlotte Rasmussen, World Health Organization, Ave Appia, Geneve 1211, Switzerland; email: rasmussenc@who.int

Novel Reassortant Highly Pathogenic Avian Influenza (H5N8) Virus in Zoos, India

Shanmugasundaram Nagarajan,¹ Manoj Kumar,¹ Harshad V. Murugkar, Sushil Tripathi, Shweta Shukla, Sonam Agarwal, Garima Dubey, Raunaq Singh Nagi, Vijendra Pal Singh, Chakradhar Tosh

Author affiliation: Indian Council of Agricultural Research–National Institute of High Security Animal Diseases, Bhopal, India

DOI: http://dx.doi.org/10.3201/eid2304.161886

Highly pathogenic avian influenza (H5N8) viruses were detected in waterfowl at 2 zoos in India in October 2016. Both viruses were different 7:1 reassortants of H5N8 viruses isolated in May 2016 from wild birds in the Russian Federation and China, suggesting virus spread during southward winter migration of birds.

Since 1996, the hemagglutinin (HA) gene of subtype H5N1 highly pathogenic avian influenza (HPAI) viruses has evolved into multiple phylogenetic clades (1). During 2010, subtype H5N8 virus, bearing an H5N1 backbone and polymerase basic (PB) protein 1 (PB1), nucleoprotein (NP), and neuraminidase (NA) genes from non-H5N1 viruses, emerged in China (2). In January 2014, a novel reassortant HPAI (H5N8) virus was detected in poultry and wild birds in South Korea (3) and subsequently spread to other counties in Asia and Europe before reaching North America by the end of 2014 (4). Because the H5N8-associated outbreaks coincided with bird migration routes, movement of wild waterfowl was suspected in intercontinental spread (5). Therefore, understanding the source and spread of the virus is a critical requirement for guidance of control measures. We report analysis of the genome of HPAI (H5N8) viruses isolated from waterfowl (domestic duck [Anas platyrhynchos domesticus] and painted stork [Mycteria leucocephala]) at 2 zoos in India in October 2016.

Twenty avian influenza viruses were isolated from 83 samples from National Zoological Park, Delhi, and Gandhi Zoological Park, Gwalior, Madhya Pradesh, India, in October 2016. The viruses were subtyped as H5N8 using reverse transcription PCR and real-time RT-PCR (online Technical Appendix 1, https://wwwnc.cdc.gov/EID/article/23/4/16-1886-Technapp1.pdf). One representative isolate each from Delhi (A/duck/India/10CA01/2016) and Madhya Pradesh (A/painted stork/India/10CA03/2016) were processed for pathogenic and molecular characterization. A detailed analysis of these isolates was performed. The viruses were identified as novel reassortants of H5N8 viruses isolated from waterfowl in Russia in 2015 and China in 2016. The novel reassortant viruses share the same 6 internal genes (PB1, PB2, PA, NC, M, and NS) and the same HA and NA genes from the H5N8 viruses isolated from waterfowl in Russia and China. The reassortant viruses differ by 7 genes from each of the Russia and China isolates. Of the 6 internal genes, the PB1, PA, NC, and NS genes were identical to those of the H5N8 viruses from Russia and China, whereas the PB2 and M genes were derived from the H5N1 virus in Asia. The HA and NA genes were derived from the H5N8 viruses from Asia. The hemagglutinin of the reassortant viruses is 99.9% identical to that of the H5N1 viruses from Asia.

These authors contributed equally to this article.